Global Companion Diagnostic Tests 麻豆原创 2024 by Company, Regions, Type and Application, Forecast to 2030

Publication ID:

GIR122413646

Publication Date:

December 30, 2024

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Companion Diagnostic Tests market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report includes an overview of the development of the Companion Diagnostic Tests industry chain, the market status of Pharmaceutical and Biotechnology Companies (Protein Detection, DNA Detection), Medical Device Companies (Protein Detection, DNA Detection), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Companion Diagnostic Tests.
Regionally, the report analyzes the Companion Diagnostic Tests markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Companion Diagnostic Tests market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Companion Diagnostic Tests market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Companion Diagnostic Tests industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Protein Detection, DNA Detection).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Companion Diagnostic Tests market.
Regional Analysis: The report involves examining the Companion Diagnostic Tests market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Companion Diagnostic Tests market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Companion Diagnostic Tests:
Company Analysis: Report covers individual Companion Diagnostic Tests players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Companion Diagnostic Tests This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Pharmaceutical and Biotechnology Companies, Medical Device Companies).
Technology Analysis: Report covers specific technologies relevant to Companion Diagnostic Tests. It assesses the current state, advancements, and potential future developments in Companion Diagnostic Tests areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Companion Diagnostic Tests market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Companion Diagnostic Tests market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Protein Detection
DNA Detection
Hybridization
Biomarker
Others
麻豆原创 segment by Application
Pharmaceutical and Biotechnology Companies
Medical Device Companies
Research Institutes
麻豆原创 segment by players, this report covers
F. Hoffman LA Roche Ltd.
QIAGEN, Illumina, Inc.
Abbott
Agilent Technologies, Inc.
Genomic Health, Inc.
BioMerieux SA, BioGenex
AGENDIA NV
Siemens Healthcare GmBH
Thermo Fisher Scientific, Inc.
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Companion Diagnostic Tests product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Companion Diagnostic Tests, with revenue, gross margin and global market share of Companion Diagnostic Tests from 2019 to 2024.
Chapter 3, the Companion Diagnostic Tests competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Companion Diagnostic Tests market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Companion Diagnostic Tests.
Chapter 13, to describe Companion Diagnostic Tests research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope of Companion Diagnostic Tests
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Companion Diagnostic Tests by Type
1.3.1 Overview: Global Companion Diagnostic Tests 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Companion Diagnostic Tests Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Protein Detection
1.3.4 DNA Detection
1.3.5 Hybridization
1.3.6 Biomarker
1.3.7 Others
1.4 Global Companion Diagnostic Tests 麻豆原创 by Application
1.4.1 Overview: Global Companion Diagnostic Tests 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Pharmaceutical and Biotechnology Companies
1.4.3 Medical Device Companies
1.4.4 Research Institutes
1.5 Global Companion Diagnostic Tests 麻豆原创 Size & Forecast
1.6 Global Companion Diagnostic Tests 麻豆原创 Size and Forecast by Region
1.6.1 Global Companion Diagnostic Tests 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Companion Diagnostic Tests 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Companion Diagnostic Tests 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Companion Diagnostic Tests 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Companion Diagnostic Tests 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Companion Diagnostic Tests 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Companion Diagnostic Tests 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 F. Hoffman LA Roche Ltd.
2.1.1 F. Hoffman LA Roche Ltd. Details
2.1.2 F. Hoffman LA Roche Ltd. Major Business
2.1.3 F. Hoffman LA Roche Ltd. Companion Diagnostic Tests Product and Solutions
2.1.4 F. Hoffman LA Roche Ltd. Companion Diagnostic Tests Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 F. Hoffman LA Roche Ltd. Recent Developments and Future Plans
2.2 QIAGEN, Illumina, Inc.
2.2.1 QIAGEN, Illumina, Inc. Details
2.2.2 QIAGEN, Illumina, Inc. Major Business
2.2.3 QIAGEN, Illumina, Inc. Companion Diagnostic Tests Product and Solutions
2.2.4 QIAGEN, Illumina, Inc. Companion Diagnostic Tests Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 QIAGEN, Illumina, Inc. Recent Developments and Future Plans
2.3 Abbott
2.3.1 Abbott Details
2.3.2 Abbott Major Business
2.3.3 Abbott Companion Diagnostic Tests Product and Solutions
2.3.4 Abbott Companion Diagnostic Tests Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Abbott Recent Developments and Future Plans
2.4 Agilent Technologies, Inc.
2.4.1 Agilent Technologies, Inc. Details
2.4.2 Agilent Technologies, Inc. Major Business
2.4.3 Agilent Technologies, Inc. Companion Diagnostic Tests Product and Solutions
2.4.4 Agilent Technologies, Inc. Companion Diagnostic Tests Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Agilent Technologies, Inc. Recent Developments and Future Plans
2.5 Genomic Health, Inc.
2.5.1 Genomic Health, Inc. Details
2.5.2 Genomic Health, Inc. Major Business
2.5.3 Genomic Health, Inc. Companion Diagnostic Tests Product and Solutions
2.5.4 Genomic Health, Inc. Companion Diagnostic Tests Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Genomic Health, Inc. Recent Developments and Future Plans
2.6 BioMerieux SA, BioGenex
2.6.1 BioMerieux SA, BioGenex Details
2.6.2 BioMerieux SA, BioGenex Major Business
2.6.3 BioMerieux SA, BioGenex Companion Diagnostic Tests Product and Solutions
2.6.4 BioMerieux SA, BioGenex Companion Diagnostic Tests Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 BioMerieux SA, BioGenex Recent Developments and Future Plans
2.7 AGENDIA NV
2.7.1 AGENDIA NV Details
2.7.2 AGENDIA NV Major Business
2.7.3 AGENDIA NV Companion Diagnostic Tests Product and Solutions
2.7.4 AGENDIA NV Companion Diagnostic Tests Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 AGENDIA NV Recent Developments and Future Plans
2.8 Siemens Healthcare GmBH
2.8.1 Siemens Healthcare GmBH Details
2.8.2 Siemens Healthcare GmBH Major Business
2.8.3 Siemens Healthcare GmBH Companion Diagnostic Tests Product and Solutions
2.8.4 Siemens Healthcare GmBH Companion Diagnostic Tests Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Siemens Healthcare GmBH Recent Developments and Future Plans
2.9 Thermo Fisher Scientific, Inc.
2.9.1 Thermo Fisher Scientific, Inc. Details
2.9.2 Thermo Fisher Scientific, Inc. Major Business
2.9.3 Thermo Fisher Scientific, Inc. Companion Diagnostic Tests Product and Solutions
2.9.4 Thermo Fisher Scientific, Inc. Companion Diagnostic Tests Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Thermo Fisher Scientific, Inc. Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Companion Diagnostic Tests Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Companion Diagnostic Tests by Company Revenue
3.2.2 Top 3 Companion Diagnostic Tests Players 麻豆原创 Share in 2023
3.2.3 Top 6 Companion Diagnostic Tests Players 麻豆原创 Share in 2023
3.3 Companion Diagnostic Tests 麻豆原创: Overall Company Footprint Analysis
3.3.1 Companion Diagnostic Tests 麻豆原创: Region Footprint
3.3.2 Companion Diagnostic Tests 麻豆原创: Company Product Type Footprint
3.3.3 Companion Diagnostic Tests 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Companion Diagnostic Tests Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Companion Diagnostic Tests 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Companion Diagnostic Tests Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Companion Diagnostic Tests 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Companion Diagnostic Tests Consumption Value by Type (2019-2030)
6.2 North America Companion Diagnostic Tests Consumption Value by Application (2019-2030)
6.3 North America Companion Diagnostic Tests 麻豆原创 Size by Country
6.3.1 North America Companion Diagnostic Tests Consumption Value by Country (2019-2030)
6.3.2 United States Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Companion Diagnostic Tests Consumption Value by Type (2019-2030)
7.2 Europe Companion Diagnostic Tests Consumption Value by Application (2019-2030)
7.3 Europe Companion Diagnostic Tests 麻豆原创 Size by Country
7.3.1 Europe Companion Diagnostic Tests Consumption Value by Country (2019-2030)
7.3.2 Germany Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Companion Diagnostic Tests Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Companion Diagnostic Tests Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Companion Diagnostic Tests 麻豆原创 Size by Region
8.3.1 Asia-Pacific Companion Diagnostic Tests Consumption Value by Region (2019-2030)
8.3.2 China Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Companion Diagnostic Tests Consumption Value by Type (2019-2030)
9.2 South America Companion Diagnostic Tests Consumption Value by Application (2019-2030)
9.3 South America Companion Diagnostic Tests 麻豆原创 Size by Country
9.3.1 South America Companion Diagnostic Tests Consumption Value by Country (2019-2030)
9.3.2 Brazil Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Companion Diagnostic Tests Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Companion Diagnostic Tests Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Companion Diagnostic Tests 麻豆原创 Size by Country
10.3.1 Middle East & Africa Companion Diagnostic Tests Consumption Value by Country (2019-2030)
10.3.2 Turkey Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Companion Diagnostic Tests 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Companion Diagnostic Tests 麻豆原创 Drivers
11.2 Companion Diagnostic Tests 麻豆原创 Restraints
11.3 Companion Diagnostic Tests Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Companion Diagnostic Tests Industry Chain
12.2 Companion Diagnostic Tests Upstream Analysis
12.3 Companion Diagnostic Tests Midstream Analysis
12.4 Companion Diagnostic Tests Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

F. Hoffman LA Roche Ltd.
QIAGEN, Illumina, Inc.
Abbott
Agilent Technologies, Inc.
Genomic Health, Inc.
BioMerieux SA, BioGenex
AGENDIA NV
Siemens Healthcare GmBH
Thermo Fisher Scientific, Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.